Sign up Australia
Proactive Investors - Run By Investors For Investors

S&P/ASX 200 closes up 35 points as investors recover a bit of poise

S&P/ASX 200 has gained ground on Tuesday, with NAB survey showing a business sentiment rebound.
man in front of trading screens
Miners are making gains and banks recover

S&P/ASX 200 (INDEXASX: XJO) (ASX:XJO) closed 0.6% up at 5,856, with miners the strongest performers.

National Australia Bank's business confidence index jumped 6 points to 19 points in January, which is materially above the long-run average of 5 points.

Midday: S&P/ASX 200 gains ground with miners advancing

BHP Billiton (ASX:BHP) gained 1.1% and Rio Tinto (ASX:RIO) shares are up 1.7%. Banks were also recovering a bit of ground after yesterday's banking commission-related losses.

11.01am: S&P/ASX 200 up 0.1%

The ASX200 is trading up 7 points or 0.1% to 5,828.

Boral Limited (ASX:BLD) is down 2.74%, Challenger Ltd (ASX:CGF) is down 2.88% and Cochlear Limited (ASX:COH) is down $2.61%.

Pre-market wrap: S&P/ASX 200 set to open strongly after Dow Jones closes up 410 points

S&P/ASX 200 will look to follow the US's lead as the Dow Jones Industrial Average (INDEXDJX: .DJI) increased 1.70% or 410 points on Monday.

Similarly, the S&P 500 Index (INDEXCBOE: .INX) was up 1.39% or 36.4 points.

The AUDUSD is trading at $0.7856, up 0.52%.

S&P/ASX 200 Futures up 0.34%

The strong trading day in the US has pushed the S&P/ASX 200 Futures up 19.5 points or 0.34%.

Gold put on US$9 over the last 24 hours to be trading at US$1,324.70 and Crude Oil WTI is trading flat at US$59.31 after retreating from US$60.70 highs.



View full . profile View Profile

Proactive Investors Australia Timeline

Related Articles

Lego ball
September 14 2018
The company's latest push is a joint venture agreement with US-based entertainment firm Three Six Zero, which has steered the careers of pop stars such as Calvin Harris
Apollo 11
February 22 2018
Immersive VR, a technology company focused on the education space, was the first company Sure backed
September 20 2018
“Cello Health is successfully building its early stage asset development advisory platform for biotech clients, as well as growing its core later stage and post-launch franchise with pharmaceutical clients”

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use